Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469920 | 0.94 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1USP7MAPK14 | |
| Trifluoroacetic Acid SCHEMBL29670376 | 0.87 | F11 (0.31) | F11KLKB1 | |
| Trifluoroacetic Acid SCHEMBL22717821 | 0.86 | CTNNB1 (0.34) | HSP90AA1HSP90AB1USP7 | |
| SCHEMBL24469835 | 0.83 | CRBN (0.39) | HSP90AA1HSP90AB1USP7MAPK14 | |
| SCHEMBL24469782 | 0.81 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1USP7MAPK14 | |
| SCHEMBL24470105 | 0.81 | USP7 (0.33) | USP7 | |
| SCHEMBL22845314 | 0.81 | GCGR (0.41) | — | |
| SCHEMBL22717418 | 0.80 | EGLN1 (0.37) | HSP90AA1HSP90AB1USP7 | |
| SCHEMBL24484171 | 0.80 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1USP7 | |
| SCHEMBL24470063 | 0.80 | MTOR (0.35) | HSP90AA1HSP90AB1USP7MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | HSP90AA1 3280/4885HSP90AB1 3455/4885USP7 3629/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | HSP90AA1 3280/4885HSP90AB1 3455/4885USP7 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.